First 10 runs free
    Intelligence Feed event · Equity · 2026-11-08

    Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales

    Question

    Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales

    Direct answer

    Eli Lilly raised its 2026 full-year revenue outlook by $5.5 billion at the midpoint, establishing a target band of $91 billion to $92 billion compared to previous guidance of $85 billion to $87 billion. The upward revision highlights accelerating prescription volumes for its metabolic franchises Mounjaro and Zepbound. Despite trading at an elevated valuation multiple of 47 times price-to-earnings following a 57% advance, sustained volumetric uptake underscores persistent pricing power and commercial supply chain clearance across domestic and export markets.

    Original publisher
    Market Ontology
    Evidence through
    2026-11-08
    Published
    2026-11-08
    Revision
    1 · 2026-11-08

    Cite as: Market Ontology, “Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales”, revision 1, evidence through 2026-11-08. https://marketontology.com/market-events/2026-11-08/eli-lilly-raised-2026-revenue-guidance-by-5-5b-to-91b-92b-on-glp-1-sales-ebdb65

    EQUITY
    Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales
    Eli Lilly raised its 2026 full-year revenue outlook by $5.5 billion at the midpoint, establishing a target band of $91 billion to $92 billion compared to previous guidance of $85 billion to $87 billion. The upward revision highlights accelerating prescription volumes for its metabolic franchises Mounjaro and Zepbound. Despite trading at an elevated valuation multiple of 47 times price-to-earnings following a 57% advance, sustained volumetric uptake underscores persistent pricing power and commercial supply chain clearance across domestic and export markets.
    LLYNVO
    Impact
    84
    YESTERDAY
    SIG
    88%
    LLYNVO
    Eli Lilly raised 2026 revenue guidance by $5.5B to $91B-$92B on GLP-1 sales
    Eli Lilly raised its 2026 full-year revenue outlook by $5.5 billion at the midpoint, establishing a target band of $91 billion to $92 billion compared to previous guidance of $85 billion to $87 billion. The upward revision highlights accelerating prescription volumes for its metabolic franchises Mounjaro and Zepbound. Despite trading at an elevated valuation multiple of 47 times price-to-earnings following a 57% advance, sustained volumetric uptake underscores persistent pricing power and commercial supply chain clearance across domestic and export markets.
    → A $5.5 billion upward revision to full-year net revenue lifts forward EPS consensus for LLY, supporting high-multiple mega-cap healthcare index weights.
    Impact
    Eli Lilly raised its 2026 full-year revenue outlook by $5.5 billion at the midpoint, establishing a target band of $91 billion to $92 billion compared to previous guidance of $85 billion to $87 billion. The upward revision highlights accelerating prescription volumes for its metabolic franchises Mounjaro and Zepbound. Despite trading at an elevated valuation multiple of 47 times price-to-earnings following a 57% advance, sustained volumetric uptake underscores persistent pricing power and commercial supply chain clearance across domestic and export markets.
    Affected
    LLYNVO
    Transmission
    A $5.5 billion upward revision to full-year net revenue lifts forward EPS consensus for LLY, supporting high-multiple mega-cap healthcare index weights.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYupward revisions to forward consensus revenue and operating cash flowUp1-4wCompany raised 2026 revenue guidance to $91-92 billion from $85-87 billion.
    NVOcompetitive duopoly market share rebalancing in GLP-1 therapiesMixed1-4wNovo Nordisk competes directly in the global metabolic and weight-loss market.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards